Heparin-induced thrombocytopenia pathophysiology is now known to be a complex process that involves platelets, vascular endothelium. and leukocytes/lymphocytes. The activation products from these sites also contribute to the activation of coagulation and fibrinolytic deficit. While many of the markers of hemostatic activation processes have been found to be increased during the acute phase of heparin-induced thrombocytopenia syndromes, the circulating levels of soluble adhesion molecules such as the P, E. and L selectins, and intracellular and vascular cell adhesion molecules have not been reported, Since the pathophysiology of heparin-induced thrombocytopenia involves the activation of platelets, endothelium, and leukocytes, it is expected that the activation products related to these hemostatic systems including soluble selectins and cellular adhesion molecules will also be increased in circulating blood, These alterations may also provide an index of the pathophysiologic process, With the availability of highly sensitive enzyme-linked immunosorbent assays for soluble P. E. and L selectins, intracellular and vascular cell adhesion molecules, it is now possible to measure these adhesion molecules
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The most catastrophic complications of therapies using heparin and related agents is recognized to be the heparin-induced thrombocytopenia (HIT) and HIT associated with thrombosis syndrome (HIlTS) (1-3). The reported prevalence of these complications with untruetionated heparin (UFH) is 2%-3% in individuals exposed to UFH. However, a lower frequency of this complication has been reported in patients treated with low molecular weight heparins (LMWHs). Patients developing HIT suffer from complications such as myocardial infarction (MI). stroke (arterial thrombotic disease). venous thrombosis. pulmonary embolism (PE). and smaller Manuscript received July 15, Il)l)l); accepted July 30, Il)l)l). This research was partly supported by a grant from the Novartis Foundation tor Therapeutic Research. Nurnbcrg, Germany.
Address correspondence and reprint requests to Dr. Jawed Farced. Ph.D .. in biological fluids. This study reports on the circulating levels of various adhesion molecules in patients with heparin-induced thrombocytopenia and their modulation after therapeutic interventions by the use of direct thrombin inhibitors. With the availability of recombinant hirudin, it is now possible to treat these patients with alternate antithrombin agents. However, the immunoactivation of platelets and other cells as shown here indicates the possible need for additional adjunct therapeutic approaches to suppress their participation in the thrombotic process. The reported increase in the circulating levels of the soluble adhesion molecules during the heparin-induced thrombocytopenia and heparin-induced thrombocytopenia with thrombosis syndrome suggests that the antiheparin platelet factor 4 antibody is capable of modulating their regulation. The prognostic role of these mediators in the management of heparin-induced thrombocytopenia syndrome warrants further investigation. Key Words: Selectins-Cellular adhesion molecules-Heparin-induced thrombocytopenia-Heparin-Pathophysiology. vessel occlusion characterized by complications such as diffuse mental confusion and renal failure.
The HIT pathophysiology is complex involving the activation of coagulation. tibrinolytic deficit, endothelial dysfunction. and platelet activation, Figure I depicts the multiple sites affected by HIT resulting in the release of various markers of hemostatic activation, Highly sensitive assays to measure the generation of markers of coagulation, fibrinolysis, endothelial, and platelet activation have been developed, and are currently used in the study of patients with arterial and venous thromboses (4-9), However, little is known of the generation of these markers in HIT/HIlTS syndromes, The activation of coagulation has been reported in HIT leading to a thrombophilic state due to depletion of various inhibitors such as antithrombin (AT) III, protein C, and heparin cofactor (HC) II during the thrombocytopenic phase in these patients (10), A disseminated intravascular coagulopathy (DIC)-Iike syndrome has also been reported to be as so-
Pathophysiology of
Heparin-Induced Thrombocytopenia (2, 3, 10, 15) . A list of some of these markers is given in Table I . The activation of coagulation is usually studied by measuring TF, prothrombin FI.2, thrombin-antithrombin (TAT) complex, and fibrinopeptide A. Plasminogen activator inhibitor-I and D-dimer levels have been reported to be altered in HIT patients. Platelet activation was observed by monitoring the levels of platelet factor 4 (PF 4), B-thromboglobulin, thrornboxane B 2 , endothelin, and vWF. The enzyme-linked immunosorbent assay (ELISA) for leukotriene C 4 has also demonstrated increased levels of this mediator in HIT; however, its origin is not known.
HIT. heparin-induced thrombocytopenia: HITTS. heparin-induced thrombocytopenia with thrombosis syndrome. (16) . These adhesion molecules are altered (generally upregulated) in various pathologic states, and in some instances, are released in circulating blood. Because each of these adhesion molecules is site-specific, their generation provides a useful means to study the specific activation/ dysfunction of platelets, endothelial cells, and/or leukocytes. Platelet activation results in the overexpression of Pselectin (GMP-140, LECAM-3, PADGEM, CD62P), which is a cell surface glycoprotein (GP) and plays a pivotal role in the migration of cells into tissue. This protein is found in the ex-granules of platelets and is translocated during platelet activation. Upregulation of P-selectin in ischemic or inflammatory conditions fol- ciated with HIT. The activation of coagulation is attributed to the generation of platelet-derived micropartic1es with procoagulant activity. Such activation of hemostasis in conjunction with endothelial dysfunction and fibrinolytic deficit is likely to result in thrombosis (10) (11) (12) (13) (14) . Thus, ischemic injury, vascular deficit, and microangiopathic complications are common in HIT patients.
It is now increasingly recognized that the HIT/HITTS syndrome involves endothelial cells and produces massive damage of vascular sites (11-13.15). Such factors as soluble tissue factor (sTF), angiotensin-converting enzyme (ACE), and von Willebrand factor (vWF) upregulation may also contribute to the pathophysiology of nrr. Serum from patients with HIT syndrome has been reported to upregulate TF and plasminogen activator inhibitor (PAn-I levels in in vitro systems (2) .
In HIT, the IgG complexes with heparin-platelet factor 4 on the platelet surface and activates platelets through the Fc receptor (FC'YRIIa or CD32). The platelets of HIT patients are known to have an increased number of these receptors (ranging from 700-4,000 receptors per platelet).These antibodies activate platelets resulting in the generation of platelet activation products such as thromboxane B~. serotonin. etc. Other antibodies of the IgA and IgM types can also be triggered during the platelet activation process, suggesting that non-Fe receptorrnediated activation of platelets can occur. Using flow cytometric analysis of whole blood, we have suggested that leukocytes are also involved in the pathophysiology of HIT. Platelet-leukocyte complexes have been found in Studies where HIT serum was incubated with whole blood.
Various molecular markers of hemostatic activation in lowed by translocation and subsequent release into circulating blood may be associated with various thrombogenic conditions. A report on the presence of elevated soluble P-selectin (sP-selectin) levels in patients with thrombotic thrombocytopenic purpura (TIP) and hemolytic uremic syndrome (HUS) and its pathophysiologic implication appeared in the early 1990s (17) . Subsequently, high levels of circulating P-selectin levels were reported in various pathologic states such as acute MI (18) . P-selectin is also found in the Weibel-Palade bodies of the endothelial cells and in the light granules of platelets. Pathologic triggers can readily mobilize P-selectin to the cell surface and its subsequent release into the circulation. Thus in HIT, antibody-mediated activation of platelets and endothelial injury can result in an increase in sP-selectin levels in circulating blood. E-selectin (endothelial leukocyte adhesion molecule, ELAM-I, CD62E) is aIlS kd cell surface GP (19) . It is transiently expressed on vascular endothelial cells in response to ischemia, injury, and cytokines such as interleukin (IL)-I and tumor necrosis factor (TN P)-o. Tissue factor and thrombin may also cause its overexpression (20) . The E-selectin overexpression and increased plasma levels of this adhesion molecule represent endothelial dysfunction/damage. Thus, the HIT antibodymediated insult to the endothelial cells lining the vascular tree can be readily assessed by measuring sE-selectin in plasma (21) (22) (23) .
Another form of selectins, the human L-selectin (LAM-I, LECAM-I, LECCAM-I, TQI, CD62L, LEU8, DREG, lymph node homing receptor, MEL-14 antigen) is a cell surface GP that is expressed constitutively on a wide variety of leukocytes (23, 24) . L-selectin consists of an amino terminal cationic-dependent lectin domain, an endothelial growth factor (EGF)-like site, two CRP-like domains, a transmembrane sequence, and a short cytoplasmic domain. This adhesion molecule plays a role in the migration of lymphocytes into peripheral lymph nodes and sites of chronic inflammation and of leukocytes into acute inflammatory sites. In conjunction with P-selectin, L-selectin mediates the initial interaction of circulating leukocytes with endothelial cells that produce a typical rolling of the cells on the endothelium. The initial interaction followed by stronger interactions results in the extravasation of leukocytes at the site of intlammation subsequently resulting in the activation and the release of various factors that lead to ischemic injury, vascular distress, and oxidative damage. Lselectin leaks from the leukocytes by proteolytic cleavage of the cell surface GP during inflammation. Therefore, during HIT/HITIS, it is likely that L-selectin is released due to the pathophysiologic activation of leukocytes.
Other adhesion molecules such as the ICAMs and Type II HIT represents a complex pathophysiologic syndrome involving platelets, endothelial cells, and leukocytes. The primary pathophysiology is due to an immune-mediated reaction, most commonly caused by the antibody (antiheparin-platelet factor 4; mainly IgG) that binds to platelets in the presence of heparin and activates platelets. This antibody is also capable of causing endothelial damage and ischemic insult at multiple sites. In the process of endothelial damage, leukocytes are recruited, and hence, become activated. This eventually results in additional pathologic responses due to the release of various mediators/growth factors from leukocytes and the on-site vascular injury. In the overall pathophysiologic process, cellular activation may result in the release of selectins from various sites including endothelium, platelets, and leukocytes/lymphocytes. This process is depicted in Fig. 2 . P-selectins can be released from platelets through the anti-heparin-platelet factor 4 antibody-mediated activation. Similarly. endothelial damage can result in the release of both P-and Eselectins, Leukocyte recruitment to vascular sites and subsequent activation may result in an increased level of L-selectin.
Currently, the pathophysiology of the HIT/HITIS syndromes is a focus of many clinical and basic science investigations, and although there is involvement of platelets, endothelium, and leukocytes, no information on the upregulation of these adhesion molecules on cellular surfaces or in the circulating blood is available from the published studies. From the discussion point-of-view on the pathophysiologic mechanisms involved in the HIT/HITIS syndrome, it is likely that the adhesion molecules play an important role in the overall pathophysiology of these syndromes. This article reports on the circulating levels of soluble po, E-, and L-selectins, and slCAM and sVCAM levels in clinically established HIT/ HITIS patients. Not only for the diagnosis and the understanding of the pathophysiology of HIT/HITIS, but also for the better clinical management of these patients will this information be useful.
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CIRCULATING ADHESION MOLECULES IN HIT PATIENTS
To determine the circulating levels of various adhesion molecules, blood samples were collected from patients recruited into a clinical trial (ARG 911 Study) where the antithrombin agent, argatroban (Novastan, Texas Biotechnology Corporation, Houston, TX, U.S.A.), was used as an alternate anticoagulant in heparin compromised HIT patients. A substudy on 30-40 sets of samples was designed using commercially available ELISA kits (R&D Systems, Minneapolis, MN, U.S.A.). Samples were obtained during pretreatment, and at 24 and 72 hours of treatment with argatroban at an infusion dose (2-10 u.g/kg/min), which maintained the aPTT in the range of 60-100 seconds. Samples from normal male/female individuals (n = 20) were also collected as a control. Selectin levels were also measured in HIT patients treated with other direct thrombin agents (such as hirulog and hirudin) as alternate anticoagulation. All blood samples were collected in 3.8% sodium citrate. Centrifuged immediately, and frozen at -70°C for a period of up to 6 months. All samples were thawed at room temperature. centrifuged to remove debris and other par-tiCUlate materials (if any), and analyzed in duplicate for various adhesion molecules using the methods according to the manufacturer's directions.
A comparison of the sP-selectin level in normal plasma and plasmas obtained from patients under treatment for HIT at pretreatment, and 24 and 72 hours during treatment periods is shown in Fig. 3 . The normal Pselectin levels were 26 ± 7 ng/mL, whereas a markedly higher P-selectin level was found in HIT patients (98 ± 10 ng/mL). At 24 hours, the P-selectin levels decreased to 79 ± 8 ng/mL, and within 72 hours of argatroban treatment, the levels were at 68 ± 6 ng/mL. This data indicates that in comparison to normals. HIT patients had three-to fourfold higher levels of sP-selectin. Treatment of HIT patients with an antithrombin drug (argatroban) resulted in a decrease of P-selectin. This may be due to the discontinuation of heparin and the inhibition of thrombin generated during HIT. Since thrombin plays an important role in the activation of platelets through microparticle formation, the P-selectin level downregulation may be related to this effect. The circulating levels of sE-selectin in HIT patients treated with argatroban is shown in Fig. 4 . The levels of soluble E-selectin were higher than the sP-selectin in normal individuals (64 ± 12 ng/mL). Heparin-induced thrombocytopenia patients exhibited relatively higher levels of sE-selectin levels prior to the argatroban treatment (96 ± 19 ng/mL); however, this data showed a wide scatter. Argatroban infusion in the HIT patients resulted in a modest decrease at the 24-and 72-hour treatment period. While the results may not be significantly different between the pretreatment and treatment periods, there was a trend towards a decrease in sE-selectin. Argatroban treatment, the inhibition of thrombin generation, platelet activation. and the role(s) of other serine proteases may be responsible for this decrease in sE-selectin levels. As shown in Fig. 2 , the antiheparin-platelet factor 4 antibodies are capable of producing the activation of endothelial cells directly. However. thrombin and other proteases generated during the HIT syndrome may also contribute to the leakage of soluble E-selectin. The observed increase in E-selectin may also be due to the indirect effect of other pathophysiologic trigger mechanism(s) resulting in vascular dysfunction. Soluble L-selectin represents a specific adhesion molecule that is constitutively expressed on a wide variety of leukocytes. Since the pathophysiology of HIT also involves leukocytes/lymphocytes. the measurement of leakage L-selectin may prove to be useful in the understanding of the overall pathophysiology of HIT and for potential developmental, diagnostic, and prognostic measures. Figure 5 shows the results of the sL-selectin levels as measured in normals and HIT patients. The circulating levels of sL-selectin in normal individuals were found to be markedly different from the soluble P-and Eselectins. The normal levels were 1,247 ± 128 ng/mL. Consistent with the other selectin data, argatroban treatment resulted in a decreased level at 24 hours (1.538 ± 140 ng/mL) and 72 hours (1,380 ± 184 ng/mL). The baseline levels in these patients were higher than the Ctin Appl Thrombo ..i../Hemostusis, Vol. 5, Supp]. I, 1999
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The results on the sP-selectin levels in a HIT patient treated with another direct antithrombin agent (hirulog) at pretreatment, and 24-and 48-hour treatment are shown in Fig. 6 . In this patient, the baseline sP-selectin level Was higher than the normal and a decrease was noted in the 24-and 48-hour hirulog treatment samples. However, the 24-hour sample did not exhibit additional reduction of the P-selectin level, in contrast to what was observed in the argatroban-treated patients. The lack of further reduction may be due to the patient's own pathophysiologic activation mechanism or may be a characteristic of the drug used, as argatroban and hirulog differ in how they mediate their effects.
The results of the sP-selectin levels in three patients who were treated with another direct thrombin inhibitor, recombinant (rj-hirudin, are shown in Fig. 7 . The pretreatment levels were markedly higher than that of norrnal individuals. A marked decrease in P-selectin was observed with treatment for 6 and 24 hours with rhirudin. Since different thrombin inhibitors exhibit different pharmacologic effects, the differences in Pselectin level decrease between argatroban, hirulog and r-hirudin may be due to different mechanisms and sites Where these drugs inhibit platelets and other aspects of the thrombotic process.
More recently, ELISA-based assays for the quantitation of sICAM and sVCAM have become available. To date, there is no report available on the levels of these cellular adhesion molecules in HIT/HITTS patients. Table 2 shows the results obtained in clinically verified patients with H1T/HITTS and a comparison to the normal controls. The sICAM and sVCAM levels are elevated in blood samples drawn from patients with clinically confirmed HIT/HITTS. The clinical relevance of these cellular adhesion molecules to the pathophysiology of HIT/HITTS syndrome is not known at this time: however, leukocyte interactions and vascular thrombi are frequently observed in patients with active HIT/HITTS syndrome.
DISCUSSION
The HIT/HITTS pathophysiology is multicomponent involving several plasmatic and cellular sites. The antibodies (anti heparin-platelet factor 4) generated during the acute phase of this syndrome are known to activate platelets and produce injury to the vasculature. Direct antibody-mediated and indirect mechanisms arc in-HIT. heparin-induced thrombocytopenia; ICAM. intracellulur adhesion molecule; VCAM, vascular cell adhesion molecule.
TAnLE 2. Soluble ICAM and VCAM levels in clinically confirmed HIT patients
Pretreatment 24 hours 48 hours Post-treatment FIG. 6. Soluble P·selectin levels in a HIT patient treated with thrombin inhibitor, hirulog. Hirulqg was administered as a bolus fOllowed by an infusion that was adjusted using the aPTT (60-90 seconds). Citrated blood samples were drawn at varying periods of time and soluble P-seleclin levels were measured using an ELISA-based assay (R&D Systems). aPTT, activated partial thromboplastin time; ELISA, enzyme-linked immunosorbent as-Say; HIT, heparin-induced thrombocytopenia; P-selectin, platelet selectin. HIT patients (n = (7) 290 ± 32 ng/mL 760 ± 60 ng/lllL cu« AI'I)I Tbrombosis/Hemostasis, Vol. 5. S/lI'I'I. I. 19W volved; however. additional information is needed from investigations of the effects of these HIT antibodies. Initial activation of platelets and endothelium also results in the subsequent involvement of blood cells such as leukocytes and lymphocytes. The inflammatory nature of HIT/H1TTS and the activation of various components of hemostasis also involve the cellular upregulation of adhesion molecules (such as ICAM. VCAM. and selectins). Uncontrolled generation of serine proteases and other enzymes leads to the leakage of various cellular adhesion molecules into circulating blood. The upregulation of these adhesion molecules on cellular surfaces and higher circulating levels of these mediators also contribute to the pathophysiology of this complex syndrome. Thus, the quantitation of these soluble adhesion molecules may not only be useful in early diagnosis, but also in the treatment of the complex HIT/HITTS syndrome. Therefore, drugs that down-regulate adhesion molecules. antiadhesion molecule antibodies, anti platelet, and endothelial targeting drugs may be useful as adjunct agents in the overall management of the HIT/HITTS syndrome.
